Efficacy and Safety of the Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Regimen for Chronic Hepatitis C in Hemodialysis Patients


Tosun G. G. , Sultanova F., Nihan A. K. , HIZEL K.

MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, vol.8, 2019 (Journal Indexed in ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 8
  • Publication Date: 2019
  • Doi Number: 10.4274/mjima.galenos.2019.2019.16
  • Title of Journal : MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS

Abstract

Introduction: A higher percentage of sustained virologic response (SVR) has been reported with the introduction of direct-acting antivirals (DAAs) to the treatment of hepatitis C in recent years. However, there are still relatively limited data on the effectiveness and safety of the use of DAAs in hemodialysis patients. The aim of this study was to evaluate the efficacy and safety of chronic hepatitis C treatment with paritaprevir/ritonavir/ ombitasvir and dasabuvir (3D) in hemodialysis patients.